Value
6.2/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 4.7 |
| Fwd P/E | 5.4 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 23.7x
- ▸PEG: 0.00
ARQT · Why this verdict
Why Arcutis Biotherapeutics (ARQT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Arcutis is generating 60% revenue growth and has crossed into free-cash-flow-positive territory despite GAAP losses, supporting a risk/reward of roughly 2.5-to-1 with 17.7% upside to the analyst consensus target; however, all revenue is concentrated in a single product franchise with a single API supplier, the RSI is stretched at 79, and the most recent quarter missed estimates after three consecutive beats — the setup is attractive but fragile.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company is free-cash-flow-positive despite reporting a GAAP loss, the combined revenue-growth-and-margin metric stands at 61 — well into elite territory — and the balance-sheet health score is a perfect 9 of 9, demonstrating a business transitioning from cash consumer to cash generator. Quality breakdown | The company sustains positive free cash flow for each of the next two reported quarters, confirming the transition is durable rather than a single-quarter event. | →Stable |
| CounterFree cash flow turning positive at a 1% margin leaves virtually no cushion; a single quarter of accelerated sales force spend, manufacturing buildup, or working capital changes could tip it back negative and prompt a re-rating of the profitability narrative. | ||
Revenue is growing at 60% year over year, one of the strongest organic growth profiles in the peer cohort; at this pace the total revenue base could roughly double within two years, providing operating leverage that can convert GAAP losses into profitability. Growth breakdown | Revenue growth stays above 40% YoY for the next two reported quarters, sustaining the trajectory that supports the current valuation. | →Stable |
| CounterRevenue growing at 60% carries a high embedded expectation; if growth decelerates meaningfully, the forward multiple could compress sharply, and the most recent earnings miss is an early signal that execution risk is real. | ||
The entire commercial operation is built on a single product franchise, and the active pharmaceutical ingredient is sourced from a single supplier; any manufacturing disruption, supply shortage, or competitive pressure on that one product would simultaneously remove the company's only material revenue stream. Bear case | Revenue growth stays above 30% YoY for 4 consecutive quarters, indicating neither supply disruption nor franchise saturation has occurred. | →Stable |
| CounterThe franchise may continue rapid adoption without encountering supply disruptions; if growth sustains at current levels for multiple additional quarters, the concentration appears to be a strength in the near term rather than an active vulnerability. | ||
The relative strength index stands at 79, entering overbought territory, and the most recent quarter missed estimates by 55% — a combination of technical stretch and execution stumble that raises the risk of a near-term pullback even as the longer-term trend remains intact. Momentum breakdown | EPS beats consensus by more than 10% in the next reported quarter, demonstrating the most recent miss was not the start of a deteriorating trend. | →Stable |
| CounterThe three quarters preceding the most recent miss produced an average beat of more than 75%; overbought conditions in fast-growing names can persist if commercial momentum is accelerating, and a single quarter's miss in a high-growth story may carry limited forward signal. | ||
The stock sits roughly 17.7% below the analyst consensus target, and the risk/reward ratio stands at approximately 2.5-to-1 in your favor — providing material upside relative to defined downside even though the full asymmetry threshold has not been cleared. Price targets | The stock reaches the analyst consensus target near $30 within 12 months, delivering the projected 17.7% return. | →Stable |
| CounterShort interest at 14% signals that a meaningful fraction of the market expects the stock to underperform; if the next quarter also misses, that short pressure could accelerate a decline that eliminates the current favorable geometry. | ||
The company is free-cash-flow-positive despite reporting a GAAP loss, the combined revenue-growth-and-margin metric stands at 61 — well into elite territory — and the balance-sheet health score is a perfect 9 of 9, demonstrating a business transitioning from cash consumer to cash generator.
→StableQuality breakdown
- Expectation
- The company sustains positive free cash flow for each of the next two reported quarters, confirming the transition is durable rather than a single-quarter event.
CounterFree cash flow turning positive at a 1% margin leaves virtually no cushion; a single quarter of accelerated sales force spend, manufacturing buildup, or working capital changes could tip it back negative and prompt a re-rating of the profitability narrative.
Revenue is growing at 60% year over year, one of the strongest organic growth profiles in the peer cohort; at this pace the total revenue base could roughly double within two years, providing operating leverage that can convert GAAP losses into profitability.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 40% YoY for the next two reported quarters, sustaining the trajectory that supports the current valuation.
CounterRevenue growing at 60% carries a high embedded expectation; if growth decelerates meaningfully, the forward multiple could compress sharply, and the most recent earnings miss is an early signal that execution risk is real.
The entire commercial operation is built on a single product franchise, and the active pharmaceutical ingredient is sourced from a single supplier; any manufacturing disruption, supply shortage, or competitive pressure on that one product would simultaneously remove the company's only material revenue stream.
→StableBear case
- Expectation
- Revenue growth stays above 30% YoY for 4 consecutive quarters, indicating neither supply disruption nor franchise saturation has occurred.
CounterThe franchise may continue rapid adoption without encountering supply disruptions; if growth sustains at current levels for multiple additional quarters, the concentration appears to be a strength in the near term rather than an active vulnerability.
The relative strength index stands at 79, entering overbought territory, and the most recent quarter missed estimates by 55% — a combination of technical stretch and execution stumble that raises the risk of a near-term pullback even as the longer-term trend remains intact.
→StableMomentum breakdown
- Expectation
- EPS beats consensus by more than 10% in the next reported quarter, demonstrating the most recent miss was not the start of a deteriorating trend.
CounterThe three quarters preceding the most recent miss produced an average beat of more than 75%; overbought conditions in fast-growing names can persist if commercial momentum is accelerating, and a single quarter's miss in a high-growth story may carry limited forward signal.
The stock sits roughly 17.7% below the analyst consensus target, and the risk/reward ratio stands at approximately 2.5-to-1 in your favor — providing material upside relative to defined downside even though the full asymmetry threshold has not been cleared.
→StablePrice targets
- Expectation
- The stock reaches the analyst consensus target near $30 within 12 months, delivering the projected 17.7% return.
CounterShort interest at 14% signals that a meaningful fraction of the market expects the stock to underperform; if the next quarter also misses, that short pressure could accelerate a decline that eliminates the current favorable geometry.
Per-dimension breakdown
Quality
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.3 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.1 |
| FCF quality | 3.2 |
| Moat | 6.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 10.0 |
- ▸FCF-positive despite GAAP loss (FCF margin 1%, FCF yield 0.1%)
- ▸Rule of 40: 61 (elite)
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 60% YoY
Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 85)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 23%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $731,970 (0.021% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.7 |
| quality rank | 6.0 |
| growth rank | 7.0 |
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.3 |
| 52w position | 7.7 |
Risk (lower is worse)
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.1 |
| days to cover | 2.6 |
| volatility | 1.5 |
| put call | 0.0 |
| implied vol | 0.3 |
| max pain risk | 3.0 |
| beta | 4.9 |
| debt equity | 7.4 |
- ▸Elevated put/call: 8.67
- ▸High IV: 78%
- ▸Above max pain $15
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.5<1.5@spot
Warning (0)
none
Reward-to-Risk
0.46
Upside
+7.0%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 85
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.52>1.3, MCap $3.4B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.5<1.5@spot.
The strongest dimensions are Growth at 10.0, Catalyst at 6.7, and Momentum at 6.5; the weakest are Risk (lower is worse) at 2.9, Technical at 2.9, and Insider at 3.8. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.46 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue is growing at 60% year over year, one of the strongest organic growth profiles in the peer cohort; at this pace the total revenue base could roughly double within two years, providing operating leverage that can convert GAAP losses into profitability.
Trip ifRevenue growth falls below 30% YoY for 2 consecutive quarters.
- P2The company is free-cash-flow-positive despite reporting a GAAP loss, the combined revenue-growth-and-margin metric stands at 61 — well into elite territory — and the balance-sheet health score is a perfect 9 of 9, demonstrating a business transitioning from cash consumer to cash generator.
Trip ifFree cash flow falls below $0 for 2 consecutive quarters, signaling the company has reverted from cash generator to cash consumer.
- P3The entire commercial operation is built on a single product franchise, and the active pharmaceutical ingredient is sourced from a single supplier; any manufacturing disruption, supply shortage, or competitive pressure on that one product would simultaneously remove the company's only material revenue stream.
Trip ifRevenue growth stays above 30% YoY for 4 consecutive quarters, demonstrating no franchise or supply disruption has occurred.
- P4The relative strength index stands at 79, entering overbought territory, and the most recent quarter missed estimates by 55% — a combination of technical stretch and execution stumble that raises the risk of a near-term pullback even as the longer-term trend remains intact.
Trip ifEPS beats consensus by more than 10% in the next reported quarter, showing the most recent miss was not the beginning of a deteriorating earnings trend.
- P5The stock sits roughly 17.7% below the analyst consensus target, and the risk/reward ratio stands at approximately 2.5-to-1 in your favor — providing material upside relative to defined downside even though the full asymmetry threshold has not been cleared.
Trip ifStock price falls below $22 within 6 months, eliminating the current favorable risk/reward geometry.